Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical. Patients with high-risk features such as PSA doubling time (PSADT) ≤ 9-12 months warrant earlier imaging for metastasis detection and consideration for intensified therapy (beyond intermittent androgen deprivation alone) during this phase of BCR-only disease. The BCR phase represents a unique opportunity to impact disease survival and delay metastasis progression. There is compelling evidence from the EMBARK trial that ADT monotherapy is no longer the optimal consideration for high-risk BCR patients.
Current treatment options in oncology. 2024 Jan 03 [Epub ahead of print]
Lauren Folgosa Cooley, Abhishek Srivastava, Neal D Shore
Atlantic Urology Clinics, Myrtle Beach, SC, USA., Atlantic Urology Clinics, Myrtle Beach, SC, USA. .